342 related articles for article (PubMed ID: 6373933)
21. Activation of macrophage cytostatic and cytotoxic activity in vitro by liposomes containing a new lipophilic muramyl peptide derivative, MDP-L-alanyl-cholesterol (MTP-CHOL).
Phillips NC; Moras ML; Chedid L; Petit JF; Tenu JP; Lederer E; Bernard JM; Lefrancier P
J Biol Response Mod; 1985 Oct; 4(5):464-74. PubMed ID: 3935756
[TBL] [Abstract][Full Text] [Related]
22. Therapy of spontaneous lung metastasis of murine renal adenocarcinoma by systemic administration of liposomes containing the macrophage activator CGP 31362.
Dinney CP; Bucana CD; Utsugi T; Fidler IJ; von Eschenbach AC; Killion JJ
Cancer Res; 1991 Jul; 51(14):3741-7. PubMed ID: 1905975
[TBL] [Abstract][Full Text] [Related]
23. Macrophage activation: synergism between hybridoma MAF and poly(I). Poly(C) delivered by liposomes.
Pidgeon C; Schreiber RD; Schultz RM
J Immunol; 1983 Jul; 131(1):311-4. PubMed ID: 6408176
[TBL] [Abstract][Full Text] [Related]
24. Synergism between human recombinant gamma-interferon and muramyl dipeptide encapsulated in liposomes for activation of antitumor properties in human blood monocytes.
Saiki I; Sone S; Fogler WE; Kleinerman ES; Lopez-Berestein G; Fidler IJ
Cancer Res; 1985 Dec; 45(12 Pt 1):6188-93. PubMed ID: 3933823
[TBL] [Abstract][Full Text] [Related]
25. The generation of tumoricidal activity in macrophages for the treatment of established metastases.
Fidler IJ
Symp Fundam Cancer Res; 1983; 36():421-35. PubMed ID: 6382518
[No Abstract] [Full Text] [Related]
26. Potent in situ activation of murine lung macrophages and therapy of melanoma metastases by systemic administration of liposomes containing muramyltripeptide phosphatidylethanolamine and interferon gamma.
Fidler IJ; Fan D; Ichinose Y
Invasion Metastasis; 1989; 9(2):75-88. PubMed ID: 2496047
[TBL] [Abstract][Full Text] [Related]
27. Differential effects of liposome-incorporation on liver macrophage activating potencies of rough lipopolysaccharide, lipid A, and muramyl dipeptide. Differences in susceptibility to lysosomal enzymes.
Daemen T; Veninga A; Dijkstra J; Scherphof G
J Immunol; 1989 Apr; 142(7):2469-74. PubMed ID: 2926140
[TBL] [Abstract][Full Text] [Related]
28. Comparative effect of muramyl dipeptide in vivo and in vitro on the tumoricidal activity of rat peritoneal macrophages.
Reisser D; Jeannin JF; Lagadec P; Martin F
J Biol Response Mod; 1985 Oct; 4(5):460-3. PubMed ID: 4078593
[TBL] [Abstract][Full Text] [Related]
29. Activation of murine Kupffer cell tumoricidal activity by liposomes containing lipophilic muramyl dipeptide.
Phillips NC; Rioux J; Tsao MS
Hepatology; 1988; 8(5):1046-50. PubMed ID: 2971013
[TBL] [Abstract][Full Text] [Related]
30. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide.
Fidler IJ; Sone S; Fogler WE; Barnes ZL
Proc Natl Acad Sci U S A; 1981 Mar; 78(3):1680-4. PubMed ID: 6940181
[TBL] [Abstract][Full Text] [Related]
31. Effect of cisplatin, lipopolysaccharide, muramyl dipeptide and recombinant interferon-gamma on murine macrophages in vitro. I. Macrophage-mediated tumor cell lysis.
Geetha B; Sodhi A
Nat Immun Cell Growth Regul; 1989; 8(2):100-7. PubMed ID: 2503714
[TBL] [Abstract][Full Text] [Related]
32. The activation of tumoricidal properties in human blood monocytes by muramyl dipeptide requires specific intracellular interaction.
Fogler WE; Fidler IJ
J Immunol; 1986 Mar; 136(6):2311-7. PubMed ID: 2936824
[TBL] [Abstract][Full Text] [Related]
33. [Antitumoral activation of rat peritoneal macrophages by muramyl dipeptide in vitro].
Reisser D; Jeannin JF; Martin F
C R Seances Acad Sci III; 1982 Nov; 295(8):485-8. PubMed ID: 6819063
[TBL] [Abstract][Full Text] [Related]
34. Delivery of macrophage-augmenting factors encapsulated in liposomes for destruction of tumor metastases.
Schroit AJ; Fidler IJ
Prog Clin Biol Res; 1982; 102 pt A():347-55. PubMed ID: 7167445
[No Abstract] [Full Text] [Related]
35. Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.
Nakajima H; Fujiwara H; Takai Y; Izumi Y; Sano S; Tsuchida T; Hamaoka T
J Immunol; 1985 Sep; 135(3):2199-205. PubMed ID: 3894520
[TBL] [Abstract][Full Text] [Related]
36. Rapid decay of tumoricidal activity and loss of responsiveness to lymphokines in inflammatory macrophages.
Poste G; Kirsh R
Cancer Res; 1979 Jul; 39(7 Pt 1):2582-90. PubMed ID: 87267
[TBL] [Abstract][Full Text] [Related]
37. Activation of tumoricidal properties in murine macrophages by intravenous injection of muramyl dipeptide encapsulated within liposomes as a treatment for spontaneous metastasis.
Fidler IJ; Poste G
Prog Clin Biol Res; 1981; 75B():257-67. PubMed ID: 7323097
[No Abstract] [Full Text] [Related]
38. Activation of murine macrophages. I. Different pattern of activation by poly I:C than by lymphokine or LPS.
Taramelli D; Varesio L
J Immunol; 1981 Jul; 127(1):58-63. PubMed ID: 6787132
[TBL] [Abstract][Full Text] [Related]
39. Liposomal muramyl dipeptide therapy of experimental M5076 liver metastases in mice.
Phillips NC; Tsao MS
Cancer Immunol Immunother; 1991; 33(2):85-90. PubMed ID: 2036662
[TBL] [Abstract][Full Text] [Related]
40. The in situ induction of tumoricidal activity in alveolar macrophages by liposomes containing muramyl dipeptide is a thymus-independent process.
Fidler IJ
J Immunol; 1981 Oct; 127(4):1719-20. PubMed ID: 6974201
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
